Vincerx Pharma Files 2024 10-K After Reverse Stock Split
Ticker: VINC · Form: 10-K · Filed: Mar 27, 2025 · CIK: 1796129
| Field | Detail |
|---|---|
| Company | Vincerx Pharma, Inc. (VINC) |
| Form Type | 10-K |
| Filed Date | Mar 27, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, reverse-stock-split, pharmaceutical
TL;DR
Vincerx Pharma filed its 2024 10-K, showing adjusted share data post-reverse split.
AI Summary
Vincerx Pharma, Inc. filed its 2024 10-K on March 27, 2025, reporting its fiscal year ending December 31, 2024. The company previously underwent a 1-for-20 reverse stock split in January 2025, with all share data adjusted accordingly. Vincerx Pharma, Inc. is located at 260 Sheridan Avenue, Suite 400, Palo Alto, CA 94306.
Why It Matters
This filing provides a comprehensive overview of Vincerx Pharma's financial performance and operational status for the fiscal year 2024, including the impact of a recent reverse stock split on its share structure.
Risk Assessment
Risk Level: medium — The company has undergone a reverse stock split, which can sometimes indicate financial distress or a strategy to meet exchange listing requirements, warranting closer examination.
Key Numbers
- 1-for-20 — Reverse Stock Split (Effected in January 2025, impacting all share data.)
- 2024-12-31 — Fiscal Year End (The period covered by the 10-K filing.)
- 2025-03-27 — Filing Date (The date the 10-K was submitted to the SEC.)
Key Players & Entities
- Vincerx Pharma, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-27 (date) — Filing date
- January 2025 (date) — Date of reverse stock split
- 1-for-20 (dollar_amount) — Reverse stock split ratio
- 260 Sheridan Avenue, Suite 400, Palo Alto, CA 94306 (company) — Business and mailing address
- Vincera Pharma, Inc. (company) — Former company name
- LifeSci Acquisition Corp. (company) — Former company name
FAQ
What was the primary reason for the 1-for-20 reverse stock split in January 2025?
The filing states that stockholders approved, and the Company effected a 1-for-20 reverse stock split in January 2025. Specific reasons beyond stockholder approval are not detailed in this excerpt.
How has the reverse stock split affected the reported share and per-share data?
All share and per-share data have been retroactively adjusted throughout the report to account for the 1-for-20 reverse stock split.
What is Vincerx Pharma, Inc.'s Standard Industrial Classification (SIC) code?
Vincerx Pharma, Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
What were Vincerx Pharma's former company names?
Vincerx Pharma, Inc. was formerly known as Vincera Pharma, Inc. (name change effective 2020-12-23) and prior to that, LifeSci Acquisition Corp. (name change effective 2019-12-06).
What is the business address of Vincerx Pharma, Inc.?
The business address is 260 Sheridan Avenue, Suite 400, Palo Alto, CA 94306.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 27, 2025 regarding Vincerx Pharma, Inc. (VINC).